CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing treatments for brain and central nervous system cancers, announced its participation in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference. CEO John Climaco presented at the event, sharing insights about his leadership journey and passion for the company's development programs.
The presentation is now available for viewing on virtualinvestorco.com and the Events page in the Investors section of cnspharma.com.
CNS Pharmaceuticals (NASDAQ:CNSP), una società biofarmaceutica specializzata nello sviluppo di trattamenti per tumori cerebrali e del sistema nervoso centrale, ha annunciato la sua partecipazione alla conferenza virtuale on-demand "What's Your Story" Summer Spotlight organizzata da Virtual Investor. Il CEO John Climaco ha preso parte all'evento, condividendo la sua esperienza di leadership e la passione per i programmi di sviluppo dell'azienda.
La presentazione è ora disponibile per la visione su virtualinvestorco.com e nella pagina Eventi nella sezione Investitori di cnspharma.com.
CNS Pharmaceuticals (NASDAQ:CNSP), una compañía biofarmacéutica enfocada en el desarrollo de tratamientos para cánceres cerebrales y del sistema nervioso central, anunció su participación en la conferencia virtual bajo demanda "What's Your Story" Summer Spotlight de Virtual Investor. El CEO John Climaco presentó en el evento, compartiendo su experiencia en liderazgo y su pasión por los programas de desarrollo de la empresa.
La presentación ya está disponible para su visualización en virtualinvestorco.com y en la página de Eventos dentro de la sección de Inversores en cnspharma.com.
CNS Pharmaceuticals (NASDAQ:CNSP)는 뇌 및 중추신경계 암 치료제 개발에 주력하는 생명공학 회사로, Virtual Investor가 주최하는 가상 투자자 "What's Your Story" 여름 스포트라이트 온디맨드 컨퍼런스에 참여한다고 발표했습니다. CEO 존 클리마코가 행사에서 발표하며 리더십 여정과 회사 개발 프로그램에 대한 열정을 나누었습니다.
발표 내용은 현재 virtualinvestorco.com과 cnspharma.com 투자자 섹션의 이벤트 페이지에서 시청할 수 있습니다.
CNS Pharmaceuticals (NASDAQ:CNSP), une société biopharmaceutique spécialisée dans le développement de traitements pour les cancers du cerveau et du système nerveux central, a annoncé sa participation à la conférence virtuelle à la demande "What's Your Story" Summer Spotlight organisée par Virtual Investor. Le PDG John Climaco a pris la parole lors de l'événement, partageant son parcours de leadership et sa passion pour les programmes de développement de l'entreprise.
La présentation est désormais disponible en visionnage sur virtualinvestorco.com ainsi que sur la page Événements dans la section Investisseurs de cnspharma.com.
CNS Pharmaceuticals (NASDAQ:CNSP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Behandlungen für Hirn- und ZNS-Krebs spezialisiert hat, gab seine Teilnahme an der virtuellen Investorenkonferenz "What's Your Story" Summer Spotlight On-Demand bekannt. CEO John Climaco präsentierte auf der Veranstaltung und teilte Einblicke in seinen Führungsweg sowie seine Leidenschaft für die Entwicklungsprogramme des Unternehmens.
Die Präsentation ist jetzt auf virtualinvestorco.com sowie auf der Veranstaltungsseite im Investorenbereich von cnspharma.com verfügbar.
- None.
- None.
– Video webcast now available on-demand
HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
As part of the event, Mr. Climaco dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development.
The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page of the Investors section of the Company's website (cnspharma.com).
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, progressive neoplastic disease, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears to have both an excellent safety profile and high tolerability among patients.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
When did CNS Pharmaceuticals (CNSP) participate in the Virtual Investor Summer Spotlight Conference?
Where can I watch the CNS Pharmaceuticals (CNSP) Virtual Investor Conference presentation?
Who presented for CNS Pharmaceuticals (CNSP) at the Virtual Investor Conference?
What type of treatments does CNS Pharmaceuticals (CNSP) develop?
